Sucralose is a pharmacologically or chemically characterised molecule whose biological activity, physicochemical properties, and toxicological profile have been evaluated to establish its health-based exposure limits for pharmaceutical manufacturing. Its molecular structure—defined by NMR, IR, mass spectrometry, and elemental analysis—determines receptor binding, metabolic transformation pathways, and chemical reactivity relevant to both therapeutic utility and toxicological risk assessment. ADME parameters including oral bioavailability, plasma protein binding, volume of distribution, and metabolic clearance inform toxicokinetic modelling applied during PDE derivation.
The severe toxicity modifier F4 in PDE derivation for Sucralose is applied when the nature of the critical adverse effect warrants additional conservatism beyond the default interspecies and intraspecies uncertainty factors.
